March 24, 2022 -- Waters has introduced a new software alongside analytical columns to assist in the drug development and biomolecule discovery process. The Waters Intact Mass app on waters_connect enables the confirmation of the mass and purity of biomolecules in a process that is twice as fast as current commercial technologies, the company said.
The streamlined process uses the BioAccord liquid chromatography-mass spectrometry (LC-MS) system to conduct mass analysis, which is essential at all stages of drug development. In particular, the process has great utility for analysis of biologics, assisting biochemists in carrying out this process with high efficiency, speed, and reliability, the company said.
Furthermore, Waters' line of analytical columns used for analysis of biomolecules complements this technology. The Acquity Premier and XBridge Premier Protein bridged/ethyl hybrid (BEH) C4 300Å column are used in the BioAccord LC-MS system and function to prevent the loss of sample analytes due to adsorption that occurs during the analysis. This further improves sensitivity for low-level intact mass analysis as well as intact mass analysis of phosphorylated proteins and low-level monoclonal antibody subunits, Waters said.
Intact mass analysis on the Waters BioAccord LC-MS system. Image courtesy of Waters.
Copyright © 2022 scienceboard.net